While I'm not opposed to paying up for a strong growth story,
particularly in an area like molecular diagnostics (MDx), I think there
are too many questions about the basic business model at Luminex (LMNX)
to pay up for this stock today. The company does indeed have
significant potential and large addressable markets, but the combination
of inherent business model volatility, less than full control on
product development, and rampant technological and commercial
competition are all significant factors as well.
Please read the full Seeking Alpha article here:
Luminex Has Both Many Opportunities And Many Questions To Answer
No comments:
Post a Comment